The impact of state policy on the costs of HIV infection

被引:24
作者
Goldman, DP [1 ]
Leibowitz, AA
Joyce, GF
Shapiro, MF
Bozzette, SA
机构
[1] RAND Corp, Santa Monica, CA 90406 USA
[2] Univ Calif Los Angeles, Los Angeles, CA USA
[3] Univ Calif San Diego, La Jolla, CA 92093 USA
[4] Vet Affairs San Diego Healthware Syst, San Diego, CA USA
关键词
D O I
10.1177/107755870105800102
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
There is substantial variation in the generosity of public assistance programs that affect HIV+ patients, and these differences should affect the economic outcomes associated with HN infection. This article uses data from a nationally representative sample of HIV+ patients to assess how differences across states in Medicaid and AIDS Drug Assistance Programs (ADAP) affect costs and labor marker outcomes for HIV+ patients in care in that state. Making ADAP programs more generous in terms of drug coverage would reduce per patient total monthly costs, mainly through a reduction in hospitalization costs. In contrast, expanding ADAP eligibility by increasing the income threshold would increase the total cost of care. Expanding eligibility for Medicaid through the medically needy program would increase per patient total costs, but full-time employment would increase and so would monthly earnings. The authors conclude that more generous state policies toward HIV+ patients-especially those designed to provide access to efficacious treatment-could improve the economic outcomes associated with HIV.
引用
收藏
页码:31 / 53
页数:23
相关论文
共 39 条
[1]  
Andersen R, 2000, HEALTH SERV RES, V35, P389
[2]  
BALAMUTH E, 1965, NATL CTR HLTH STAT, V7
[3]   The care of HIV-infected adults in the United States [J].
Bozzette, SA ;
Berry, SH ;
Duan, NJ ;
Frankel, MR ;
Leibowitz, AA ;
Lefkowitz, D ;
Emmons, CA ;
Senterfitt, JW ;
Berk, ML ;
Morton, SC ;
Shapiro, MF .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (26) :1897-1904
[4]  
Centers for Disease Control and Prevention, 1997, HIV AIDS SURVEILLANC, V9, P1
[5]  
COHEN SB, 1985, J ECON SOC MEAS, V13, P125
[6]   Loss of cytomegalovirus (CMV) viraemia following highly active antiretroviral therapy in the absence of specific anti-CMV therapy [J].
Deayton, J ;
Mocroft, A ;
Wilson, P ;
Emery, VC ;
Johnson, MA ;
Griffiths, PD .
AIDS, 1999, 13 (10) :1203-1206
[7]   HIV-1 protease inhibitors - A review for clinicians [J].
Deeks, SG ;
Smith, M ;
Holodniy, M ;
Kahn, JO .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (02) :145-153
[8]   Changes to AIDS dementia complex in the era of highly active antiretroviral therapy [J].
Dore, GJ ;
Correll, PK ;
Li, YM ;
Kaldor, JM ;
Cooper, DA ;
Brew, BJ .
AIDS, 1999, 13 (10) :1249-1253
[9]  
DOYLA A, 2000, NATL ADAP MONITORING
[10]  
DOYLE A, 1998, NATL ADAP MONITORING